Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

	ZyVersa Therapeutics, Inc.
	(Name of Issuer)
	Common Stock, par value $0.0001 per share
	(Title of Class of Securities)
	98987D 102
	(CUSIP Number)
	Jared Kelly Lowenstein Sandler LLP One Lowenstein Drive Roseland, NJ 07068 (212) 419-5974
	(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
	April 28, 2023
	(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 98987D 102

SCHEDULE 13D

Page 2 of 6 Pages

 

1	NAME OF REPORTING PERSONS   Stephen Glover
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS   OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF	7	SOLE VOTING POWER	1,420,283*
SHARES BENEFICIALLY	8	SHARED VOTING POWER	0*
OWNED BY EACH	9	SOLE DISPOSITIVE POWER	1,420,283*
REPORTING PERSON WITH	10	SHARED DISPOSITIVE POWER	0*

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   1,420,283*
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   6.76%*
14	TYPE OF REPORTING PERSON   IN

 

*As of the date hereof, Stephen Glover (the “Reporting Person”) may be deemed to beneficially own an aggregate of 1,420,283 shares of common stock, par value $0.0001 per share (“Common Stock”), of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Issuer”). The shares of Common Stock reported herein include 627,834 shares of Common Stock issued to the Reporting Person and affiliates in the Business Combination (as defined below), consisting of (i) 448,909 shares of Common Stock held directly by the Reporting Person; (ii) 43,847 shares of Common Stock held by MedicaRx Inc.; (iii) 85,442 shares of Common Stock held by Asclepius Life Sciences Fund, L.P.; and (iv) 49,636 shares of Common Stock held by Asclepius Master Fund, LTD. The shares of Common Stock reported herein assume (i) the exercise of options and warrants exercisable as of or within 60 days of the date hereof for 683,143 and 91,806 shares, respectively, of Company common stock and (ii) the conversion and exercise of PIPE Shares and PIPE Warrants, respectively, for an aggregate of 17,500 shares of Company common stock. The Reporting Person is the managing director of MedicaRx Inc., the managing director of Asclepius Master Fund, LTD, and the managing member of Asclepius Life Sciences Fund, L.P. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to beneficially own 1,420,283 shares of Common Stock, representing 6.76% of the Common Stock of the Issuer deemed issued and outstanding as of the date hereof. The Reporting Person disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

 

The beneficial ownership percentage is based on 20,225,263 shares of Common Stock reported as issued and outstanding in the Issuer’s Form 10-Q filed with the Securities Exchange Commission on May 12, 2023.

 

 

CUSIP No. 98987D 102

SCHEDULE 13D

Page 3 of 6 Pages

 

Explanatory Note

 

This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D filed on behalf of Stephen Glover (the “Reporting Person”), with the Securities and Exchange Commission (the “SEC”) on December 12, 2022 (the “Schedule 13D”). Except as specifically provided herein, this Amendment No. 1 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

 

 

CUSIP No. 98987D 102

SCHEDULE 13D

Page 4 of 6 Pages

 

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

 

Item 5 of the Schedule 13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:

 

(a-b) The Reporting Person may be deemed to beneficially own (with sole voting and dispositive power) 1,420,283 shares of Common Stock, which represents approximately 6.76% of the Issuer’s issued and outstanding shares of Common Stock.

 

(c) Except as described in this Schedule 13D, there have been no transactions in the shares of Common Stock effected by the Reporting Person during the past sixty days.

 

(d) Not applicable.

 

(e) Not applicable.

 

 

CUSIP No. 98987D 102

SCHEDULE 13D

Page 5 of 6 Pages

 

ITEM 7. MATERIAL REQUIRED TO BE FILED AS EXHIBITS

 

The following exhibits are incorporated into this Schedule 13D.

 

Exhibit 1		Business Combination Agreement, dated July 20, 2022 (filed as Exhibit 2.1 to the Issuer’s Current Report on Form 8-K as filed on July 22, 2022, and incorporated herein by reference).
Exhibit 2		Shareholder Support Agreement, dated as of July 20, 2022 (filed as Exhibit 10.3 to the Issuer’s Current Report on Form 8-K as filed on July 22, 2022, and incorporated herein by reference).
Exhibit 3		Lock-Up Agreement dated as of July 20, 2022 (filed as Exhibit 10.4 to the Issuer’s Current Report on Form 8-K as filed on July 22, 2022, and incorporated herein by reference).
Exhibit 4		Executive Employment Agreement, by and between the Issuer and Stephen Glover dated as of September 13, 2022 (filed as Exhibit 10.16 to the Issuer’s Current Report on Form 8-K as filed on December 13, 2022, and incorporated herein by reference).

 

 

CUSIP No. 98987D 102

SCHEDULE 13D

Page 6 of 6 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 12, 2023	By:	/s/ Stephen C. Glover
		Stephen C. Glover

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).